Disease-modifying therapies

Disease-modifying therapies

Despite advances in insulin therapy and glucose monitoring, managing type 1 diabetes remains challenging, and therapeutic options are limited. There is an urgent need for disease-modifying interventions that target the autoimmune basis of the disease to prevent, delay, or alter its progression. Such approaches could substantially improve quality of life and long-term health outcomes.

Disease-modifying therapies projects

Overview of all projects
1/1/2025
-
12/31/2028
Age-related heterogeneity in response to disease-modifying therapies in new-onset type 1 diabetes

Promotors:

Chantal Mathieu

Conny Gysemans

Pierre Lemaitre

10/1/2024
-
9/30/2030
Personalized precision medicine for the prevention and reversal of type 1 diabetes: a stepwise approach

Promotors:

Chantal Mathieu

Conny Gysemans

Kristina Casteels

Lut Overbergh

Pierre Lemaitre

8/7/2022
-
8/7/2026
Characterization of the dynamic immunophenotype during type 1 diabetes progression to identify predictive biomarkers of anti-CD3 mono- and combination therapy in disease prevention and reversal in mice

Promotors:

Chantal Mathieu

Conny Gysemans

Amber Wouters

8/1/2019
-
5/31/2023
Novel immunotherapies to prevent or arrest type 1 diabetes

Promotors:

Chantal Mathieu

Conny Gysemans

Pieter-Jan Martens

9/1/2014
-
12/6/2019
A novel L. lactis-based antigen-specific platform for the treatment of type 1 diabetes: essential steps towards successful clinical translation.

Promotors:

Chantal Mathieu

Dana Cook

1/1/2013
-
12/31/2016
Optimizing antigen-specific immunotherapy in type 1 diabetes.

Promotors:

Chantal Mathieu

Conny Gysemans

Hannelie Korf

6/1/2012
-
12/22/2016
Boosting beta-cell function for treatment of type 1 diabetes.

Promotors:

Chantal Mathieu

Conny Gysemans

João Paulo Monteiro Carvalho Mori Cunha

10/1/2009
-
9/16/2013
Novel immunotherapies in type 1 diabetes: exploring antigen-specific and non-specific approaches.

Promotors:

Chantal Mathieu

Conny Gysemans

Tatiana Takiishi

9/1/2008
-
7/17/2014
ActoBiotics for antigen-specific intervention in type 1 diabetes: mono- and combination therapy.

Promotors:

Chantal Mathieu

Conny Gysemans

Sofie Robert

Support us

Choose to make a direct impact by contributing to a specific research project or by supporting the overarching goals of the Hippo & Friends Type 1 Diabetes Fund. 

By donating today, you enable early-career scientists to pursue groundbreaking research aimed at preventing and reversing the onset of symptomatic type 1 diabetes. Every contribution moves us one step closer to breakthroughs that matter.

I want to make a direct donationI want to support Hippo & Friends

Other research lines